Only endothelial cells express the glycoprotein known as E-Selectin (CD62E). It was initially identified as a leukocyte adhesion molecule on activated endothelial cells by Bevilacqua and associates in the 1980s. Skin and bone marrow microvessels produce E-Selectin on a constitutive basis, but endothelial cells in other tissues do not, although their expression is significantly increased by inflammatory cytokines like TNF- and IL-1. Although not fully understood, the release of a soluble version of E-Selectin and the internalization of the molecule have been proposed as explanations for this fast upregulation. The control of leukocyte accumulation in inflammatory reactions may depend on this modulation of E-Selectin expression.
E-Selectin has a typical molecular weight of 64 kD, although various glycosylated variants have been found to have relative molecular weights of 100 and 115 kDa. An amino-terminal lectin-like domain, an epidermal growth factor (EGF)-like domain, and six repeating motifs like those in certain complement-binding proteins make up the core structure of E-Selectin. While the function of the complement binding-like sections is not yet clear, they likely work, at least in part, as spacers to keep the other domains away from the cell surface. The lectin-like domain and EGF-like domain mediate contact with leukocytes.
Numerous structures carried by glycoproteins are recognized by E-Selectin. Based on that, CD BioGlyco provides Custom Glycoprotein Synthesis including Chemoenzymatic Synthesis and Chemical Synthesis for customers to help them produce custom glycoproteins.
Fig.1 E-Selectin, EGF-like, and two SCR domains complexed with Sialyl Lewis X. (PDB)
The expression of E-Selectin on endothelium is associated with acute or chronic inflammatory responses because E-Selectin interacts with ligands on the surface of immune cells to facilitate the recruitment of immune cells. And E-Selectin has a detrimental role not just in inflammatory diseases but has also been found in several cancer tissues, suggesting a possible role in the development of this illness. Adhesion of tumor cells on the vascular endothelium of the target organ is a key step in the cascade of metastasis. The pair SLEx/E-Selectin is now well established as a key mediator in the adherence of cancer cells to the endothelium during the development of metastases through a process akin to immune cell adhesion. Leukocyte transmigration has been demonstrated to be inhibited by monoclonal antibodies (MABs) directed against E-Selectin. According to some theories, when leukocytes attach to E-Selectin on active endothelium, CD11b (Mac-1) on the leukocytes is upregulated, leading to an increase in adhesion through the interaction of ICAM-1/Mac-1.
E-Selectin has evolved into a natural target for therapeutic intervention as a result of this demonstrated expression of E-Selectin in the vicinity of inflammation, infection, or malignancy. The use of E-Selectin as a receptor for the administration of anti-inflammatory or anti-cancer medications as well as for medical imaging systems comprising an imaging agent is a significant tactic.
Fig.2 Schematic representation of the different concepts used to target E-Selectin. (Jubeli, et al., 2012)
CD BioGlyco has an advanced Microarray Platform for customers to explore the functions of E-Selectins. We have confidence to meet customers’ requirements about sciences research, if you are interested in our services, please feel free to contact us for more information.
References
About Us
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
Contact Us
